Atea Pharmaceuticals, Inc. (AVIR) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
AVIR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AVIR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 52.4% | 39.4% | 34.5% |
Download Data
Export AVIR earnings history in CSV or JSON format
Free sign-in required to download data
Atea Pharmaceuticals, Inc. (AVIR) Earnings Overview
As of May 8, 2026, Atea Pharmaceuticals, Inc. (AVIR) reported trailing twelve-month net income of -$147M, reflecting +3.0% year-over-year growth. The company earned $-1.86 per diluted share over the past four quarters.
Looking at the long-term picture, AVIR's historical earnings data spans multiple years. The company achieved its highest annual net income of $121M in fiscal 2021.
Atea Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IOVA (-$354M net income, -148.4% margin), RDVT ($14M net income, 14.6% margin), RLAY (-$273M net income, -1800.6% margin), AVIR has comparable earnings metrics. Compare AVIR vs IOVA →
AVIR Earnings vs Peers
Earnings metrics vs comparable public companies
AVIR Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$158M | +6.0% | -$181M | $-1.94 | - | - |
| 2024 | -$168M | -23.9% | -$193M | $-2.00 | - | - |
| 2023 | -$136M | -17.3% | -$164M | $-1.63 | - | - |
| 2022 | -$116M | -195.6% | -$131M | $-1.39 | - | - |
| 2021 | $121M | +1207.1% | $138M | $1.37 | 34.5% | 39.4% |
| 2020 | -$11M | +18.7% | -$11M | $-0.13 | -22.5% | -22.7% |
| 2019 | -$13M | -48.5% | -$15M | $-0.16 | - | - |
| 2018 | -$9M | - | -$9M | $-0.90 | - | - |
See AVIR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVIR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVIR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVIR — Frequently Asked Questions
Quick answers to the most common questions about buying AVIR stock.
Is AVIR growing earnings?
AVIR EPS of $-1.86 reflects slowing growth at +3.0%, below the 5-year CAGR of N/A. TTM net income is $-147M. Expansion rate has moderated.
What are AVIR's profit margins?
Atea Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are AVIR's earnings?
AVIR earnings data spans 2018-2025. The current earnings trend is +3.0% YoY. Historical data enables comparison across business cycles.